health
Novo Nordisk’s head start on GLP-1 pills forces investors to rethink Eli Lilly's dominance
Early signs from the launch of Novo Nordisk's Wegovy pill and Eli Lilly & Co.'s Foundayo are making investors rethink the opportunity for GLP-1 pills.
TL;DR
- Novo Nordisk's Wegovy pill has seen a surge in demand since its January launch, nearly doubling daily new patients for telehealth provider LifeMD.
- The success of the Wegovy pill is forcing investors to re-evaluate the oral GLP-1 market, challenging the initial expectation that Eli Lilly's Foundayo would dominate.
- Novo Nordisk's pill leveraged its brand recognition and a strong promotional blitz, including celebrity endorsements and a lower introductory price.
- Eli Lilly is working to build consumer awareness for Foundayo, which has a different active ingredient than its best-selling weight loss shot.
- Both oral GLP-1 medications are expanding the market by attracting patients who were hesitant about injections due to needle phobia or cost.
- Novo Nordisk is investing in manufacturing capacity for its oral products, with the Wegovy pill expected to be approved in Europe later this year.
- Analysts suggest that while the pills are significant, they won't solely define the future success of either Novo Nordisk or Eli Lilly.